HISTORICAL ARTICLE
JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Forty years of lithium treatment.

This review is based on a lecture in which I was requested to present my personal experiences and views. Since its introduction into psychiatry more than 40 years ago, lithium treatment has in most countries gained wide acceptance in the prophylaxis of unipolar and bipolar affective disorders. At one time it was feared that lithium treatment might lead to a decrease in the glomerular filtration rate, but systematically collected data indicate that even long-term treatment does not induce renal insufficiency. During treatment, regular laboratory monitoring of serum lithium and creatinine concentrations is recommended. Recent studies suggest that long-term lithium treatment does not raise the mortality of manic-depressive patients and indeed may have a mortality-lowering and antisuicidal effect. Despite the availability of alternative therapies, lithium remains the treatment of choice for the prophylaxis of recurrent manic-depressive illness.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app